MMEA
RCKT icon

Main Management ETF Advisors’s Rocket Pharmaceuticals RCKT Stock Holding History

Main Management ETF Advisors’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-76,208
Closed -$187K – 179
2025
Q2 		$187K Buy
76,208
+1,236
+2% +$6.26K 0.01% 135
2025
Q1 		$500K Buy
74,972
+45,068
+151% +$445K 0.02% 130
2024
Q4 		$376K Sell
29,904
-2,688
-8% -$40.5K 0.02% 143
2024
Q3 		$602K Buy
+32,592
New +$668K 0.03% 142

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Main Management ETF Advisors's RCKT Position: Q3 2025 in Review

Main Management ETF Advisors sold out of Rocket Pharmaceuticals (RCKT) in Q3 2025, closing a stake of 76,208 shares — an estimated $187K sold.

Main Management ETF Advisors first reported a position in RCKT in Q3 2024 and held it in 4 quarters. The position peaked at $602K in Q3 2024. 173 funds tracked by Wall St. Rank hold RCKT as of Q3 2025.

  • Main Management ETF Advisors reported no remaining Rocket Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Main Management ETF Advisors sold 76,208 Rocket Pharmaceuticals shares in Q3 2025, an estimated $187K.
  • Main Management ETF Advisors first reported a position in Rocket Pharmaceuticals in Q3 2024 and held it in 4 quarters.
  • Main Management ETF Advisors's Rocket Pharmaceuticals position peaked at $602K in Q3 2024.
  • 173 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q3 2025.

Based on Main Management ETF Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.